Molecular Research Pharma CT carries out the activities of a pharmaceutical research laboratory, with an application in the field of bioscience, biotechnology, and pharmacology, acting as a support to all companies in the portfolio of Cube Labs.
The spin-off offers support services in the development of molecules in the preclinical phase to pharmaceutical and biotech companies. Specifically, starting from the discovery and selection of new molecules, MRC deals with the non-clinical studies of pharmacology and toxicology, as well as the production of product quality data.
The procedures implemented are in accordance with GLP (Good Laboratory Practices).
The goal is to simplify the process of developing and marketing new drugs, so those new safe products can reach patients faster.
To accomplish this mission, Molecular Research Pharma CT relies on the expertise of its team and highly innovative equipment. The MRC project was born with the aim of carrying out research and development of new molecules in the therapeutic field, comprehensive of drugs active against rare diseases.